LENTECHS Revenue and Competitors

Location

N/A

Total Funding

Medical

Industry

Estimated Revenue & Valuation

  • LENTECHS's estimated annual revenue is currently $2.5M per year.(i)
  • LENTECHS's estimated revenue per employee is $226,909

Employee Data

  • LENTECHS has 11 Employees.(i)
  • LENTECHS grew their employee count by 38% last year.

LENTECHS's People

NameTitleEmail/Phone
1
President And CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Project ManagerReveal Email/Phone
4
CCOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15M830%N/AN/A
#2
$3.5M28913%N/AN/A
#3
$300M15518%N/AN/A
#4
$11.5M3827%N/AN/A
#5
$3.5M9333%N/AN/A
#6
$7.7M2547%N/AN/A
#7
$3.5M7-80%N/AN/A
#8
$3.5M8-27%N/AN/A
#9
$3.5M46-2%$43.9MN/A
#10
$7.7M25-17%N/AN/A
Add Company

What Is LENTECHS?

LENTECHS, LLC is a privately-held, clinical stage ophthalmic medical device company focused on developing a new generation of soft, suspended contact lens, with a platform of offerings to span the patient lifecycle. Its flagship contact lens platform, APIOC™ has a patented design for suspension of the lens from behind the upper eyelid and is designed based on the anatomy of the eye.\n\nCollaboratively founded with its optometrist inventors Melissa Bailey, OD, PhD, and Joe Barr, OD, MS, FAAO, LENTECHS has successfully developed its core technology licensed from The Ohio State University. APIOC for Presbyopia and APIOC for Presbyopia with Astigmatism will launch in early-2022. This new generation of soft, suspended contact lens is designed to help Presbyopes achieve glasses-like vision with the freedom of a contact lens.™\n\nLENTECHS was incorporated in 2017, is headquartered in Columbus, Ohio, and is funded by a network of investors committed to revolutionary innovation in contact lenses.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$2.5M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M110%N/A
#2
$1M1122%N/A
#3
$2.3M110%N/A
#4
$1M11-21%N/A
#5
$1.8M1157%N/A